2025. Achievement of Treat-to-Target Thresholds with Envudeucitinib, a Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Results from STRIDE and OLE. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s650. DOI:https://doi.org/10.25251/8xwzce61.